VYNE Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
VYNE and Yarrow Bioscience will merge, creating a Nasdaq-listed company focused on advancing YB-101, a first-in-class TSHR antibody for Graves' disease and TED. The combined entity is well-funded, with a strong investor syndicate and a cash runway into 2028.
-
The session highlighted advances in BET inhibitor development for autoimmune and inflammatory diseases, with Repibresib in Phase IIb for vitiligo and VYN202 in Phase Ib for psoriasis. Both assets show promising safety and efficacy, with key data readouts expected this year.
-
The conference highlighted progress on BET inhibitors for autoimmune diseases, with repibresib in phase II-B for vitiligo and VYN202 in phase I-B for psoriasis. Key differentiators include once-daily dosing and strong safety data. Results for both programs are expected in 2024–2025.
Fiscal Year 2024
-
The team is advancing two BET inhibitor programs for autoimmune diseases, with VYN-201 in phase 2b for vitiligo and VYN-202 in phase 1a for systemic indications. Strong early efficacy and safety data, a robust cash position, and multiple clinical milestones are expected over the next year.